Evidence map›Paper›PMID 36393912›Full record

ArticleAmerican journal of ophthalmology case reports2022

Lurbinectedin improves macular edema in a case of central retinal vein occlusion.

Filippo Simona, Feliciana Menna, Luciano Wannesson, Alessandro Meduri, Gabriella De Salvo, Giuseppe Querques

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Filippo SimonaPAX Eye Center, Locarno, Switzerland.
Feliciana MennaPAX Eye Center, Locarno, Switzerland.
Luciano WannessonIstituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland.
Alessandro MeduriBiomedical, Dental and Morphological and Functional Images Sciences, Department, University of Messina, Messina, Italy.
Gabriella De SalvoOphthalmology Department, University Hospital Southampton Foundation Trust, Southampton, United Kingdom.
Giuseppe QuerquesIRCCS San Raffaele Scientific Institute, University Vita-Salute, Milan, Italy.
Università della Svizzera italiana · CHUniversity Hospital Southampton NHS Foundation Trust · GBUniversity of Messina · ITVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To evaluate the response to lurbinectedin in a case of macular edema, secondary to central retinal vein occlusion (CRVO). Serial spectral domain optical coherence tomography (SD-OCT) scans were taken in a 70-year-old man with a 24-month history of macular edema secondary to CRVO in the right eye. The patient underwent 5 cycles of chemotherapy with lurbinectedin between October 2018 and May 2019. Central macular thickness (CMT) before and after each chemotherapy cycle was measured together with progression analysis using the CIRRUS Zeiss software. Observations: SD-OCT showed alternating recurrence and resolution of macular edema closely related to the chemotherapy administrations. CMT oscillated between 496 and 284 μm during the follow-up. The macular edema was showed to decrease as soon as 4 days following chemotherapy. Conclusions and importance: Resolution of macular edema associated with CRVO was seen in our patient whilst undergoing chemotherapy with lurbinectedin. Lurbinectedin may play a role in the treatment of macular edema secondary to CRVO and may open new therapeutic indication for this natural marine molecule.

Indexed as

1-central retinal vein occlusionKeyword 2-lurbinectedinKeyword 3- macular edemaKeyword 4Keyword 5Natural anticancer drugsOptical coherence tomography

Identifiers

PMID36393912
PMCPMC9650020
OpenAlexW4308289298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.